ArticleScientific reports2024
Real-time analysis of osteoclast resorption and fusion dynamics in response to bone resorption inhibitors.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Engineering osteoclast resorption unitsLab on a chip · 2026Article
- Cell fusion in osteoclastogenesis.Biochemical Society transactions · 2025Review
- Non-coding RNA modulation in osteoclasts and its implications for osteoblast lineage cell behavior in a co-culture system.Cell communication and signaling : CCS · 2025Article
- Cathepsin K inhibitors promote osteoclast-osteoblast communication and engagement of osteogenesis.JBMR plus · 2025Article
- Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers.Seminars in cancer biology · 2025Review
- Proteins and DNA Sequences Interacting with Tanshinones and Tanshinone Derivatives.International journal of molecular sciences · 2025Review
- Isolation and Generation of Osteoclasts.Methods in molecular biology (Clifton, N.J.) · 2025Article
- CU Cilia - an application for image analysis by machine learning - reveals significance of cysteine cathepsin K activity for primary cilia of human thyroid epithelial cells.Frontiers in endocrinology · 2025Article
- Emerging Role of Enzyme-Immobilized Nanocarriers in Osteoporosis: Advances and Challenges.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
Abstract
Cathepsin K (CatK), an essential collagenase in osteoclasts (OCs), is a potential therapeutic target for the treatment of osteoporosis. Using live-cell imaging, we monitored the bone resorptive behaviour of OCs during dose-dependent inhibition of CatK by an ectosteric (Tanshinone IIA sulfonate) and an active site inhibitor (odanacatib). CatK inhibition caused drastic reductions in the overall resorption speed of OCs. At IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.